Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
World game at war: why some European nations have threatened a World Cup boycott 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
 - EconoTimes)
PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English version will be available within short.
Lund, April 23, 2018
Active Biotech AB (publ)
Helén Tuvesson
CEO
For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties is in development for neurodegenerative diseases in partnership with Teva Pharmaceutical Industries Ltd. ANYARA, an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11.30 am CET on April 23, 2018..
Attachment
